Efficacy and safety of PG201 (Layla®) and celecoxib in the treatment of symptomatic knee osteoarthritis: a double-blinded, randomized, multi-center, active drug comparative, parallel-group, non-inferiority, phase III study

Rheumatology International

Volumn 34, Issue 10, 2014, Pages 1369-1378

  Yoo, Wan Hee ^a   Yoo, Han Gyul ^b   Park, Sung Hwan ^c   Baek, Han joo ^d   Lee, Yun Jong ^e   Shim, Seung Cheol ^f   Kang, Seong Wook ^g   Kim, Hyun Ah ^h   Song, Jung Soo ⁱ   Suh, Chang Hee ^j   Choi, Sung Jae ^k   Yoon, Bo Young ^l   Tae, Dong Nyeon ^m   Ko, Hyun Sook ^m   Song, Yeong Wook ⁿ  

^a Jeonbuk National University Medical School and Hospital   (South Korea)

^b UNIVERSITY OF RHODE ISLAND   (United States)

^c The Catholic University of Korea College of Medicine   (South Korea)

^d Gachon University College of Medicine   (South Korea)

^e Seoul National University Bundang Hospital   (South Korea)

^f Eulji University School of Medicine   (South Korea)

^g Chungnam National University College of Medicine   (South Korea)

^h Hallym University   (South Korea)

ⁱ Chung Ang University College of Medicine   (South Korea)

^j Ajou University School of Medicine   (South Korea)

^k Korea University College of Medicine   (South Korea)

^l Inje University   (South Korea)

^m Gyeonggi Do   (South Korea)

ⁿ Seoul National University Hospital   (South Korea)

more..

Author keywords

Celecoxib; Knee osteoarthritis; PG201

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; HERBAL EXTRACT PG201; PLANT EXTRACT; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CYCLOOXYGENASE 2 INHIBITORS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PLANT EXTRACTS; PYRAZOLES; QUALITY OF LIFE; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84918802134     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-014-2964-8     Document Type: Article

References (31)

1. Poole AR (1999) An introduction to the pathophysiology of osteoarthritis. Front Biosci 4:D662–D670
2. Vuolteenaho K, Moilanen T, Knowles RG, Moilanen E (2007) The role of nitric oxide in osteoarthritis. Scand J Rheumatol 36:247–258
3. Martel-Pelletier J, Alaaeddine N, Pelletier JP (1999) Cytokines and their role in the pathophysiology of osteoarthritis. Front Biosci 4:D694–D703
4. Goldring MB, Birkhead JR, Suen LF, Yamin R, Mizuno S, Glowacki J, Arbiser JL, Apperley JF (1994) Interleukin-1 beta-modulated gene expression in immortalized human chondrocytes. J Clin Invest 94:2307–2316
5. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P (2008) OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil 16:137–162
6. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, Gunther K, Hauselmann H, Herrero-Beaumont G, Kaklamanis P, Lohmander S, Leeb B, Lequesne M, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Serni U, Swoboda B, Verbruggen G, Zimmerman-Gorska I, Dougados M; Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT (2003) EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT). Ann Rheum Dis 3(62):1145–1155
7. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, Hauselmann HJ, Herrero-Beaumont G, Jordan K, Kaklamanis P, Leeb B, Lequesne M, Lohmander S, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Swoboda B, Varatojo R, Verbruggen G, Zimmermann-Gorska I, Dougados M, EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) (2005) EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 5(64):669–681
8. American College of Rheumatology Subcommittee on Osteoarthritis G (2000) Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 43:1905–1915
9. Gregory PJ, Sperry M, Wilson AF (2008) Dietary supplements for osteoarthritis. Am Fam Physician 77:177–184
10. Shin SS, Jin M, Jung HJ, Kim B, Jeon H, Choi JJ, Kim JM, Cho BW, Chung SH, Lee YW, Song YW, Kim S (2003) Suppressive effects of PG201, an ethanol extract from herbs, on collagen-induced arthritis in mice. Rheumatology (Oxford) 42:665–672
11. Park KC, Park EJ, Kim ER, Kim Y, Chung SH, Cho BW, Kim S, Jin M (2005) Therapeutic effects of PG201, an ethanol extract from herbs, through cartilage protection on collagenase-induced arthritis in rabbits. Biochem Biophys Res Commun 331:1469–1477
12. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M (1986) Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 29:1039–1049
13. Steinbrocker O, Traeger CH, Batterman RC (1949) Therapeutic criteria in rheumatoid arthritis. JAMA 140:659–662
14. Strand V, Kelman A (2004) Outcome measures in osteoarthritis: randomized controlled trials. Curr Rheumatol Rep 6:20–30
15. Ehrich EW, Davies GM, Watson DJ, Bolognese JA, Seidenberg BC, Bellamy N (2000) Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol 27:2635–2641
16. Angst F, Aeschlimann A, Michel BA, Stucki G (2002) Minimal clinically important rehabilitation effects in patients with osteoarthritis of the lower extremities. J Rheumatol 29:131–138
17. Bijlsma JW (2005) Patient centred outcomes in osteoarthritis. Ann Rheum Dis 64:1–2
18. Lachin JM (1981) Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials 2:93–113
19. Sheldon E, Beaulieu A, Paster Z, Dutta D, Yu S, Sloan VS (2005) Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo. Clin Ther 27:64–77
20. Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, Simon L, Strand V, Woodworth T, Dougados M (2004) OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthr Cartil 12:389–399
21. Krasnokutsky S, Attur M, Palmer G, Samuels J, Abramson SB (2008) Current concepts in the pathogenesis of osteoarthritis. Osteoarthr Cartil 16(Suppl 3):S1–S3
22. Krasnokutsky S, Samuels J, Abramson SB (2007) Osteoarthritis in 2007. Bull Hosp Jt Dis 65:222–228
23. Pelletier JP, Pelletier JM, Abramson SB (2001) Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum 44:1237–1247
24. McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS (2001) Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 30:11–18
25. Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, Geis GS (2001) Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 96:1019–1027
26. Scheiman JM, Cryer B, Kimmey MB et al (2004) A randomized, controlled comparison of ibuprofen at the maximal over-the-counter dose compared with prescription-dose celecoxib on upper gastrointestinal mucosal injury. Clin Gastroenterol Hepatol 2:290–295
27. Clegg DO, Reda DJ, Harris CL, Klein MA, O’Dell JR, Hooper MM, Bradley JD, Bingham CO 3rd, Weisman MH, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher HR Jr, Oddis CV, Wolfe F, Molitor JA, Yocum DE, Schnitzer TJ, Furst DE, Sawitzke AD, Shi H, Brandt KD, Moskowitz RW, Williams HJ (2006) Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 354:795–808
28. Sawitzke AD, Shi H, Finco MF, Dunlop DD, Harris CL, Singer NG, Bradley JD, Silver D, Jackson CG, Lane NE, Oddis CV, Wolfe F, Lisse J, Furst DE, Bingham CO, Reda DJ, Moskowitz RW, Williams HJ, Clegg DO (2010) Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis 69:1459–1464
29. Dougados M, Moore A, Yu S, Gitton X (2007) Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis. Arthritis Res Ther 9:R11
30. Tannenbaum H, Berenbaum F, Reginster JY, Zacher J, Robinson J, Poor G, Bliddal H, Uebelhart D, Adami S, Navarro F, Lee A, Moore A, Gimona A (2004) Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. Ann Rheum Dis 63:1419–1426
31. Conaghan PG, Dickson J, Bolten W, Cevc G, Rother M (2013) A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis. Rheumatology (Oxford) 2:1303–13012